ArticleBritish journal of cancer1998
Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.
Article in British journal of cancer, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 123 citations in OpenAlex.
- Gibberellin derivative GA-13315 overcomes multidrug resistance in breast cancer by up-regulating BMP6 expression.Frontiers in pharmacology · 2022Article
- Bone morphogenic proteins-2, -4, -6 and 7 in non-muscle invasive bladder cancer.Oncology letters · 2020Article
- Prostate Cancer and Bone Metastases: The Underlying Mechanisms.International journal of molecular sciences · 2019Review
- Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis.Scientific reports · 2018Article
- Role of hepcidin and iron metabolism in the onset of prostate cancer.Oncology letters · 2018Article
- Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.Bone · 2018Review
- The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.Current osteoporosis reports · 2016Review
- Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.Biochemical Society transactions · 2016Review
- Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2015Review
- Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.British journal of cancer · 2014Article
- Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.Clinical & experimental metastasis · 2014Article
- Hypermethylation leads to bone morphogenetic protein 6 downregulation in hepatocellular carcinoma.PloS one · 2014Article
- Bone morphogenetic protein 6 expression in oral cavity squamous cell cancer is associated with bone invasion.The Laryngoscope · 2013Article
- Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages.Cancer science · 2013Article
- Augmented autocrine bone morphogenic protein (BMP) 7 signaling increases the metastatic potential of mouse breast cancer cells.Clinical & experimental metastasis · 2012Article
- Article
- Steps in prostate cancer progression that lead to bone metastasis.International journal of cancer · 2011Review
- Article
- Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression.Medical oncology (Northwood, London, England) · 2010Article
- The Yin and Yang of bone morphogenetic proteins in cancer.Cytokine & growth factor reviews · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostatic adenocarcinoma commonly metastasizes to bone. Unlike most other bony secondaries, the majority of skeletal prostatic metastases are osteoblastic rather than osteolytic in nature. Several growth factors which are known to stimulate bone formation are expressed in benign and malignant prostate cells, but none has been specifically linked to osteosclerotic metastases. Bone morphogenetic proteins (BMPs) induce ectopic bone formation in vivo. We have reported previously that BMP-6 mRNA and protein are expressed in the majority of primary prostatic carcinomas with established skeletal metastases but rarely in clinically organ-confined tumours. This study examines the expression of BMP-6 mRNA in matched prostatic primary and secondary bony lesions and in isolated skeletal metastases from prostatic adenocarcinomas, as well as other common human malignancies, by in situ hybridization. BMP-6 mRNA was detected in 11 out of 13 bone metastases from prostate carcinoma and in three paired samples of primary prostate carcinoma and matching skeletal metastasis. Weak signals for BMP-6 were also present in 5 out of 17 skeletal deposits from non-prostatic malignancies. BMP-6 mRNA appears to be strongly expressed in prostatic adenocarcinomas, both in the primary tumour and in bone metastases. It is also expressed, though less frequently, in skeletal metastases from other human carcinomas. Our findings suggest that BMP-6 may hold potential as an attractive marker and possible mediator of skeletal metastases, particularly in prostate carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.